Fred Hutch

Fred Hutch Making life beyond cancer a reality. Fred Hutch is an independent, nonprofit organization that also serves as the cancer program for UW Medicine.
(584)

Together we provide the specialized focus of a top-ranked cancer center and the comprehensive services of a leading integrated health system.

03/12/2026

Did you know? 🤔 Not all nutritionists are registered dietitians — but all registered dietitians are nutritionists.

At Fred Hutch, every member of our nutrition team is a Registered Dietitian (RD), a credentialed expert with:
✔️ Extensive formal education, training, and credentials, including certifications like the Certified Specialist in Oncology Nutrition and/or a master's degree
✔️ Over 900+ hours of supervised practice
✔️ Passed a board exam
✔️ National certification and licensed by the state

Our RDs provide up‑to‑date medical nutrition therapy, using evidence‑based nutrition to help patients manage and treat medical conditions. As a CoC‑accredited cancer center, Fred Hutch follows standards requiring that cancer patients be referred only to registered dietitians for this specialized care — ensuring the highest‑quality support at every step.

Learn more: https://bit.ly/4s3OuVd

03/11/2026

Say goodbye to storing a jug of p*e in your fridge. 👋🧪

That 24‑hour urine test — yes, the one that sends a big jug to your fridge — is becoming less necessary for people with multiple myeloma.

Dr. Rahul Banerjee, a myeloma specialist at Fred Hutch, found that this test doesn’t actually give doctors better information about how patients are responding to treatment. His recent analysis suggests patients may be able to skip this uncomfortable step without losing any important insights about their care.

“It fits into my broader idea that more isn’t always better,” he says. “More data isn't always helpful, and more treatment isn't always helpful.”

When Sue Biggins, PhD, director of Fred Hutch’s Basic Sciences Division, first set out to study how cells divide, she fa...
03/10/2026

When Sue Biggins, PhD, director of Fred Hutch’s Basic Sciences Division, first set out to study how cells divide, she faced a fundamental scientific unknown. But with the help of donor support, she took a leap and made a breakthrough. Her team revealed how cells preserve their genetic information, a discovery that’s reshaping our understanding of what goes wrong in cancer and how to stop it.

🔬Today, Dr. Biggins oversees a group of nearly 30 labs exploring the
fundamental biology behind cancer and other diseases. Donor support helps
fuel the bold, curiosity-driven research that makes discoveries possible. Join us by making a gift to accelerate what’s next: https://bit.ly/4slWEb4

It was a big week for raising awareness about colorectal cancer! From kicking things off at the Washington State Capitol...
03/09/2026

It was a big week for raising awareness about colorectal cancer! From kicking things off at the Washington State Capitol in Olympia to wrapping up at the Colorectal Cancer Community Awareness Event in SeaTac, physicians, community health educators and outreach specialists from Fred Hutch, UW Medicine and community health organizations came together to share information about prevention, screening and treatment.

Scroll through a few highlights from the week! 💙

Dr. Soheil Meshinchi, a world leader in pediatric AML research, has been named the second holder of the Dylan Burke Endo...
03/09/2026

Dr. Soheil Meshinchi, a world leader in pediatric AML research, has been named the second holder of the Dylan Burke Endowed Chair in Immunotherapy. Established in 2020 by Dave Burke and Louise O’Reilly, the chair was created to accelerate innovative, immune‑based treatments for children with high‑risk blood cancers.

The endowment honors Burke's son, Dylan, who was diagnosed with myelodysplastic syndrome at age 9. He received care at Fred Hutch and Seattle Children’s, where Dr. Meshinchi became a key partner in pursuing every scientific option available — from advanced molecular analyses to emerging targeted therapies.

“We wanted to give back,” Burke said. “I’m a big believer in harnessing the body’s immune system to fight cancer. Our goal is to help accelerate the science that can make a difference for future kids.”

Read more: https://bit.ly/4l2egGw

Why are young people getting colon cancer and what are some signs to look out for? Dr Rachel Issaka answers this and mor...
03/08/2026

Why are young people getting colon cancer and what are some signs to look out for? Dr Rachel Issaka answers this and more in the SoundSide podcast. Link to podcast in comments.

We’re grateful to Representative Tarra Simmons for honoring the late patient advocate Natalie Phelps earlier this week w...
03/07/2026

We’re grateful to Representative Tarra Simmons for honoring the late patient advocate Natalie Phelps earlier this week with House Resolution 9643.

Natalie was an unwavering champion for others living with colorectal cancer. She co‑chaired the Seattle Walk to End Colon Cancer, served on the Colorectal Cancer Care Alliance’s Education Engagement Committee, and shared her message with national and international audiences through major media outlets.

We’re proud to continue Natalie’s advocacy, and we thank Rep. Simmons for taking the initiative to commemorate her life and legacy. 💙

03/07/2026

Did you know certain foods can help lower your cancer risk? Registered dietitian Ray Palko shares which nutrient‑packed options you can add to your daily routine to fuel your body and support long-term health. 🍎 🥦 🫘

Jana Batson was 31 years old and the mother of a 1‑year‑old when she was diagnosed with nodular sclerosing Hodgkin lymph...
03/05/2026

Jana Batson was 31 years old and the mother of a 1‑year‑old when she was diagnosed with nodular sclerosing Hodgkin lymphoma, a cancer of the lymph system that helps the body fight infection.

Bloodwork and an ultrasound came back without concerning findings, but she still felt something was wrong. She went to the emergency room at EvergreenHealth for a CT scan, which revealed a 10‑centimeter mass in her chest.

“I was in complete shock and instantly thought of my daughter,” said Batson, who lives in Maple Valley, southeast of Seattle. “I was just so scared. It didn’t feel real.”

After her diagnosis, her Fred Hutch care team recommended a four‑drug chemotherapy regimen followed by radiation at Fred Hutch - Proton Therapy. Since completing treatment in May 2023, her scans have shown no new growth, and her bloodwork is normal. Despite concerns about fertility after chemotherapy, Batson welcomed another baby, now almost 9 months old. Even after chest radiation, she’s been able to breastfeed without problems.

These days, Batson is enjoying being a full-time mom and working part time as a nurse at an elementary school. She tries to live in the moment and treasures her time with family, which has been central to her emotional healing.

Tap the link in comments to read more.

Follicular lymphoma, a common and usually slow-growing type of non-Hodgkin lymphoma, has long been deemed incurable: Tho...
03/04/2026

Follicular lymphoma, a common and usually slow-growing type of non-Hodgkin lymphoma, has long been deemed incurable: Though the disease responds well to initial treatment, oncologists tell patients to expect it to come back. New findings from a 15-year follow-up analysis of clinical trial patients with follicular lymphoma (FL) could upend that prediction, according to a study published in JAMA Oncology.

Scientists at SWOG, Fred Hutch Cancer Center and the University of Rochester Medical Center looked at outcomes from FL patients who had received chemoimmunotherapy: a standard chemotherapy regimen (known as CHOP) plus an antibody-based immunotherapy (either CHOP plus rituximab or CHOP plus a radio-labelled antibody). Applying cure modeling to the 15 years-worth of follow-up data, the investigators showed a cure rate of 42% in the total population of trial participants.

The new findings could inform discussions with patients newly diagnosed with follicular lymphoma, said Fred Hutch lymphoma expert Mazyar Shadman, MD, MPH, who is the paper’s first author.

The current work analyzed data from 532 patients who enrolled in a SWOG trial initiated in 2001 by the late Fred Hutch lymphoma physician-scientist Dr. Oliver "Ollie" Press.

The current analysis is the latest of multiple scientific papers to come out of the trial, initiated by Press, who mentored Shadman. He pioneered the development and use of radio-labeled antibodies, which help focus cancer-killing radiation in tumors, for lymphoma treatment. More than a decade later, the trial Press conducted is still providing insights that could improve patient care and future lymphoma research.

“It’s a wonderful testament to Ollie and his vision,” Shadman said.

Tap the link comments to read more.

03/02/2026

Colon cancer is preventable, and early action is key.
If you’re 45+, or have a family history of , now is the time to schedule your screening.
Under 45? Dr. Rachel Issaka shares practical tips to lower your risk and stay ahead of the disease.

Address

1100 Fairview Avenue N
Seattle, WA
98109

Opening Hours

Monday 7am - 9pm
Tuesday 7am - 9pm
Wednesday 7am - 9pm
Thursday 7am - 9pm
Friday 7am - 9pm
Saturday 8am - 5:30pm
Sunday 8am - 5:30pm

Telephone

+12066675000

Website

Alerts

Be the first to know and let us send you an email when Fred Hutch posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Fred Hutch:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Cures Start Here

Fred Hutchinson Cancer Research Center is dedicated to: -- Generating new scientific discoveries and translating them into effective medical practices, therapies and public health approaches. -- Recruiting, supporting and training highly qualified scientists and physicians in an environment that promotes collaboration and excellence. --Cooperating with other research entities and medical institutions to assure worldwide access to new research findings and technical developments. -- Providing sensitive, efficient and effective care for patients participating in our experimental therapies and other studies. -- Promoting the importance of scientific research, responsible medical care, healthy environments and personal behaviors through public education and advocacy.